Literature DB >> 28622291

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.

Daniel J Murphy1, Kevin G Blyth2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28622291      PMCID： PMC5563996          DOI： 10.1038/cdd.2017.97

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  10 in total

1.  Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer.

Authors:  Waël C Hanna; Narinder S Paul; Gail E Darling; Hadas Moshonov; Frances Allison; Thomas K Waddell; Marcelo Cypel; Marc E de Perrot; Kazuhiro Yasufuku; Shaf Keshavjee; Andrew F Pierre
Journal:  J Thorac Cardiovasc Surg       Date:  2013-10-18       Impact factor: 5.209

Review 2.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

3.  Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Authors:  J Mazières; F Barlesi; T Filleron; B Besse; I Monnet; M Beau-Faller; S Peters; E Dansin; M Früh; M Pless; R Rosell; M Wislez; P Fournel; V Westeel; F Cappuzzo; A Cortot; D Moro-Sibilot; J Milia; O Gautschi
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

4.  Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer?

Authors:  Traves D Crabtree; Varun Puri; Simon B Chen; David S Gierada; Jennifer M Bell; Stephen Broderick; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2014-08-08       Impact factor: 5.209

5.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

6.  Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Henri G Colt; Septimiu D Murgu; Robert J Korst; Christopher G Slatore; Michael Unger; Silvia Quadrelli
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 7.  Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis.

Authors:  Lynn Calman; Kinta Beaver; Daniel Hind; Paul Lorigan; Chris Roberts; Myfanwy Lloyd-Jones
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

8.  Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Authors:  Mariam Jamal-Hanjani; Alan Hackshaw; Yenting Ngai; Jacqueline Shaw; Caroline Dive; Sergio Quezada; Gary Middleton; Elza de Bruin; John Le Quesne; Seema Shafi; Mary Falzon; Stuart Horswell; Fiona Blackhall; Iftekhar Khan; Sam Janes; Marianne Nicolson; David Lawrence; Martin Forster; Dean Fennell; Siow-Ming Lee; Jason Lester; Keith Kerr; Salli Muller; Natasha Iles; Sean Smith; Nirupa Murugaesu; Richard Mitter; Max Salm; Aengus Stuart; Nik Matthews; Haydn Adams; Tanya Ahmad; Richard Attanoos; Jonathan Bennett; Nicolai Juul Birkbak; Richard Booton; Ged Brady; Keith Buchan; Arrigo Capitano; Mahendran Chetty; Mark Cobbold; Philip Crosbie; Helen Davies; Alan Denison; Madhav Djearman; Jacki Goldman; Tom Haswell; Leena Joseph; Malgorzata Kornaszewska; Matthew Krebs; Gerald Langman; Mairead MacKenzie; Joy Millar; Bruno Morgan; Babu Naidu; Daisuke Nonaka; Karl Peggs; Catrin Pritchard; Hardy Remmen; Andrew Rowan; Rajesh Shah; Elaine Smith; Yvonne Summers; Magali Taylor; Selvaraju Veeriah; David Waller; Ben Wilcox; Maggie Wilcox; Ian Woolhouse; Nicholas McGranahan; Charles Swanton
Journal:  PLoS Biol       Date:  2014-07-08       Impact factor: 8.029

9.  Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.

Authors:  Ken Suzawa; Shinichi Toyooka; Masakiyo Sakaguchi; Mizuki Morita; Hiromasa Yamamoto; Shuta Tomida; Tomoaki Ohtsuka; Mototsugu Watanabe; Shinsuke Hashida; Yuho Maki; Junichi Soh; Hiroaki Asano; Kazunori Tsukuda; Shinichiro Miyoshi
Journal:  Cancer Sci       Date:  2015-12-03       Impact factor: 6.716

10.  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Authors:  M Schuler; J C-H Yang; K Park; J-H Kim; J Bennouna; Y-M Chen; C Chouaid; F De Marinis; J-F Feng; F Grossi; D-W Kim; X Liu; S Lu; J Strausz; Y Vinnyk; R Wiewrodt; C Zhou; B Wang; V K Chand; D Planchard
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976
  10 in total
  5 in total

Review 1.  Liquid Biopsy to Identify Actionable Genomic Alterations.

Authors:  Sai-Hong Ignatius Ou; Misako Nagasaka; Viola W Zhu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 2.  Role of circulating tumor DNA in the management of early-stage lung cancer.

Authors:  Heng Zhao; Ke-Zhong Chen; Ben-Gang Hui; Kai Zhang; Fan Yang; Jun Wang
Journal:  Thorac Cancer       Date:  2018-03-12       Impact factor: 3.500

3.  Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.

Authors:  Cathy Zhou; Zilong Yuan; Weijie Ma; Lihong Qi; Angelique Mahavongtrakul; Ying Li; Hong Li; Jay Gong; Reggie R Fan; Jin Li; Michael Molmen; Travis A Clark; Dean Pavlick; Garrett M Frampton; Brady Forcier; Elizabeth H Moore; David K Shelton; Matthew Cooke; Siraj M Ali; Vincent A Miller; Jeffrey P Gregg; Philip J Stephens; Tianhong Li
Journal:  J Hematol Oncol       Date:  2018-11-06       Impact factor: 17.388

4.  Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations.

Authors:  Yuli Wang; Jing Li; Jian Huang; Chaoqun Wu; Li Li; Ping Gong
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

Review 5.  Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.

Authors:  Dan Yan; H Shelton Earp; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.